KennethIAtagaMD

Oncology • Memphis, TN

Hematologic Oncology

Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Ataga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ataga's full profile

Already have an account?

Office
956 Court Ave., Suite D-324
Memphis, TN 38163
Phone+1 901-448-2813

Fax+1 901-448-3206

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1997 - 2000
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1994 - 1997
University of Benin Faculty of MedicineClass of 1990

Certifications & Licensure

TN State Medical License 2018 - 2026
NC State Medical License 1997 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2011

Clinical Trials

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. Start of enrollment: 2002 Feb 01
Completed
Phase 2
Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Start of enrollment: 2004 Jun 01
Completed
Phase 2
A Safety Study of Eptifibatide in Patients With Sickle Cell Disease Start of enrollment: 2009 Jan 01
Terminated
Phase 1, Phase 2
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension Start of enrollment: 2005 Feb 01
Withdrawn
Phase 2
Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease Start of enrollment: 2009 Dec 01
Terminated
Phase 2
The Effect of Rivaroxaban in Sickle Cell Disease Start of enrollment: 2014 Feb 01
Completed
Phase 2
Kidney Function in Sickle Cell Anemia Start of enrollment: 2017 Nov 17
Active, not recruiting
A Study of SHP655 (rADAMTS13) in Sickle Cell Disease Start of enrollment: 2019 Oct 21
Completed
Phase 1
Roles: Principal Investigator
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia Start of enrollment: 2022 Jul 05
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein
The Lancet. Haematology. 2024-12-04
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia.
Laila Elsherif, Yihan Tang, Kammie L Patillo, David Wichlan, Ugochi O Ogu
British Journal of Haematology. 2024-11-01
Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia.
Rima S Zahr, Sara R Rashkin, Maria Armila Ruiz, Laila Elsherif, Guohui Ren
Haematologica. 2024-10-01

Journal Articles

Effect of Renin‐Angiotensin‐Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease
Vimal K Derebail, Kenneth I Ataga, British Journal of Haematology

Abstracts/Posters

Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia
Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Longitudinal Effect of Hydroxyurea Therapy on Left Ventricular Diastolic Function in Sickle Cell Anemia
Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia
Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Transition Continuity Promotes Long-Term Retention in Adult Care Among Young Adults with Sickle Cell Disease
Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study
Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomize...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Advancing Science in Sickle Cell Disease: Implications for the Future of Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Sickle Cell Disease Forum: Innovation in Drug Development and Emerging Science
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

TN Doctor Leading $3 Million AI Study for Predicting Kidney Function Decline in Sickle Cell PatientsOctober 30th, 2021
Promising New Sickle Cell Disease Medicine Wins FDA ApprovalNovember 18th, 2019
Novartis Adakveo Approved by FDA for Sickle Cell DiseaseNovember 16th, 2019
Join now to see all

Grant Support

Endothelial Dysfunction In The Pathogenesis Of Sickle Cell NephropathyNational Heart, Lung, And Blood Institute2012
Coagulation Activation In Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2010
Eptifibatide As Treatment For Acute Pain Episodes In Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2008–2009
Pulmonary Hypertension In Sickle Cell Disease With Identification Of Clinical AsNational Center For Research Resources2008
Clinical Trial: Phase III, Ica-17043 With Or Without Hydroxyurea In Sickle CellNational Center For Research Resources2008
Clinical Trial: Longterm Safety Of Ica-17043 With Or Without Hydroxyurea In SickNational Center For Research Resources2008
Clinical Trial: Impacts Trial: Investigation Of The Modulation Of PhospholipaseNational Center For Research Resources2008
Clinical Trial: Bosentan In Sickle Cell Patients With Symptomatic Pulmonary HypeNational Center For Research Resources2008
Clinical Trial: Bosentan In Patients With Symptomatic Pulmonary Hypertension &SNational Center For Research Resources2008
Clinical Trial: Arginine Supplementation In Sickle Cell Anemia: Physiological ANational Center For Research Resources2008
6R-BH4 In Subjects With Sickle Cell DiseaseNational Center For Research Resources2008
Effect Of Hydroxyurea On Blood Coagulation In Patient With Sickle Cell DiseaseNational Center For Research Resources2005–2008
Prevalence Of Pulmonary Hypertension In Sickle Cell DiseaseNational Center For Research Resources2004–2008
Longterm Safety Of Ica-17043 With Or Without Hydroxyurea In Sickle Cell PatientsNational Center For Research Resources2007
Bosentan In Sickle Cell Patients With Symptomatic Pulmonary HypertensionNational Center For Research Resources2007
Bosentan In Patients With Symptomatic Pulmonary Hypertension &Sickle CellNational Center For Research Resources2007
Phase III, Ica-17043 With Or Without Hydroxyurea In Sickle Cell DiseaseNational Center For Research Resources2006–2007
Arginine Supplementation In Sickle Cell Anemia: Physiological And ProphylacticNational Center For Research Resources2005–2007
The Effect Of Anticoagulation In Sickle Cell AnemiaNational Center For Research Resources2005–2006
Disordered Blood Coagulation In Sickle Cell DiseaseNational Center For Research Resources2002–2006